First Tracks Biotherapeutics (TRAX) stock: key figures, P/E, revenue and dividend

Health Care · United States · ISIN US3371851029

Price
45.23 USD
Market cap
1.57 bn USD
P/E (2025)
–
P/S (2025)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
-57.74 %
Return on assets (ROA)
-50.22 %

First Tracks Biotherapeutics financials

Fiscal year20242025
Revenue0.00 USD0.00 USD
Gross profit-152.00 m USD-139.00 m USD
EBIT-181.00 m USD-179.00 m USD
Net income-163.00 m USD-166.00 m USD
Diluted EPS – continuing operations-4.71 USD-4.78 USD

Full history since 2023, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

Sign up for freeOpen interactive view

About First Tracks Biotherapeutics

First Tracks Biotherapeutics, Inc. operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in United States. Its products includes ANB033, a novel anti-CD122 antagonist that targets the shared beta subunit of the IL-15 and IL-2 receptors; Rosnilimab, a antibody engineered to selectively deplete pathogenic T cells in both the periphery and inflamed tissues; and ANB101, a BDCA2-modulating antibody designed to specifically target plasmacytoid dendritic cells (pDCs). First Tracks Biotherapeutics, Inc. was formerly known as Biopharma Co., Inc. and changed its name to First Tracks Biotherapeutics, Inc. in February 2026. First Tracks Biotherapeutics, Inc. was founded in 2019 and is based in San Diego, California.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.